SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

NCT03161431 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma Stage III
Melanoma Stage IV

Interventions

DRUG: SX-682
BIOLOGICAL: Pembrolizumab

Sponsor

Syntrix Biosystems, Inc.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]